Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Inclusion Criteria

Concurrent Medication:

Allowed:

* Maintenance therapy for opportunistic infections.

Patients must have:

* HIV infection.
* Kaposi's sarcoma that has relapsed or progressed.
* Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions).
* NO active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for OIs is permitted).
* Consent of parent or guardian if less than 18 years of age.

NOTE:

* This study is approved for prisoner participation.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
* Grade 3 or worse peripheral neuropathy.
* Altered mental status that would prevent informed consent or prevent study compliance.

Patients with the following prior condition are excluded:

Neuropsychiatric history.

Prior Medication:

Excluded:

* Prior etoposide.
* Any other anti-KS drugs within 14 days prior to study entry.
* Any investigational drug other than antiretrovirals within 14 days prior to study entry.
* Any prior investigational agent, if given as the ONLY prior treatment for KS.

Prior Treatment:

Excluded:

* Radiation therapy within 7 days prior to study entry.

Continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.